Cognition Therapeutics, Inc. Research and Development Expense
Cognition Therapeutics, Inc. (CGTX) reported Research and Development Expense of $5.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-07
- Cognition Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $5.10M, a 55.60% decline year-over-year.
- Cognition Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $6.12M, a 43.26% decline year-over-year.
- Cognition Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $11.15M, a 36.71% increase year-over-year.
- Cognition Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $3.77M, a 66.88% decline year-over-year.
- Cognition Therapeutics, Inc. research and development expense for fiscal 2025 was $37.19M, a 10.77% decline from fiscal 2024.
- Cognition Therapeutics, Inc. research and development expense for fiscal 2024 was $41.68M, a 12.04% increase from fiscal 2023.
- Cognition Therapeutics, Inc. research and development expense for fiscal 2023 was $37.20M, a 22.66% increase from fiscal 2022.
- Cognition Therapeutics, Inc. research and development expense for fiscal 2022 was $30.32M, a 63.28% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.10M 10-Q · filed 2026-08-07 | $11.22M 10-Q · filed 2026-08-07 | $22.36M derived: sum of 3 quarters · filed 2026-08-07 | $26.14M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $6.12M 10-Q · filed 2026-05-08 | $17.27M derived: sum of 2 quarters · filed 2026-05-08 | $21.04M derived: sum of 3 quarters · filed 2026-05-08 | $32.52M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $11.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $14.92M derived: sum of 2 quarters · filed 2026-03-26 | $26.40M derived: sum of 3 quarters · filed 2026-08-07 | $37.19M 10-K · filed 2026-03-26 |
| 2025-09-30 | $3.77M 10-Q · filed 2025-11-06 | $15.25M derived: sum of 2 quarters · filed 2026-08-07 | $26.04M 10-Q · filed 2025-11-06 | $34.19M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $11.48M 10-Q · filed 2026-08-07 | $22.27M 10-Q · filed 2026-08-07 | $30.42M derived: sum of 3 quarters · filed 2026-08-07 | $41.81M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $10.79M 10-Q · filed 2026-05-08 | $18.94M derived: sum of 2 quarters · filed 2026-05-08 | $30.33M derived: sum of 3 quarters · filed 2026-05-08 | $41.91M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $8.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $19.55M derived: sum of 2 quarters · filed 2026-03-26 | $31.12M derived: sum of 3 quarters · filed 2026-03-26 | $41.68M 10-K · filed 2026-03-26 |
| 2024-09-30 | $11.39M 10-Q · filed 2025-11-06 | $22.97M derived: sum of 2 quarters · filed 2025-11-06 | $33.52M 10-Q · filed 2025-11-06 | $45.12M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $11.58M 10-Q · filed 2025-08-07 | $22.13M 10-Q · filed 2025-08-07 | $33.73M derived: sum of 3 quarters · filed 2025-08-07 | $45.40M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $10.55M 10-Q · filed 2025-05-07 | $22.15M derived: sum of 2 quarters · filed 2025-05-07 | $33.82M derived: sum of 3 quarters · filed 2025-05-07 | $42.32M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $11.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $23.27M derived: sum of 2 quarters · filed 2025-03-20 | $31.77M derived: sum of 3 quarters · filed 2025-03-20 | $37.20M 10-K · filed 2025-03-20 |
| 2023-09-30 | $11.67M 10-Q · filed 2024-11-13 | $20.17M derived: sum of 2 quarters · filed 2024-11-13 | $25.60M 10-Q · filed 2024-11-13 | $32.04M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $8.50M 10-Q · filed 2024-08-08 | $13.93M 10-Q · filed 2024-08-08 | $20.37M derived: sum of 3 quarters · filed 2024-08-08 | $28.64M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $5.43M 10-Q · filed 2024-05-07 | $11.87M derived: sum of 2 quarters · filed 2024-05-07 | $20.14M derived: sum of 3 quarters · filed 2024-05-07 | $29.24M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $6.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $14.71M derived: sum of 2 quarters · filed 2024-03-26 | $23.81M derived: sum of 3 quarters · filed 2024-03-26 | $30.32M 10-K · filed 2024-03-26 |
| 2022-09-30 | $8.27M 10-Q · filed 2023-11-02 | $17.37M derived: sum of 2 quarters · filed 2023-11-02 | $23.88M 10-Q · filed 2023-11-02 | $29.46M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $9.10M 10-Q · filed 2023-08-08 | $15.62M 10-Q · filed 2023-08-08 | $21.19M derived: sum of 3 quarters · filed 2023-08-08 | $24.86M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $6.52M 10-Q · filed 2023-05-04 | $12.09M derived: sum of 2 quarters · filed 2023-05-04 | $15.77M derived: sum of 3 quarters · filed 2023-05-04 | $20.66M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $5.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $9.25M derived: sum of 2 quarters · filed 2023-03-23 | $14.14M derived: sum of 3 quarters · filed 2023-03-23 | $18.57M 10-K · filed 2023-03-23 |
| 2021-09-30 | $3.67M 10-Q · filed 2022-11-14 | $8.57M derived: sum of 2 quarters · filed 2022-11-14 | $13.00M 10-Q · filed 2022-11-14 | $16.29M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $4.89M 10-Q · filed 2022-08-09 | $9.32M 10-Q · filed 2022-08-09 | $12.61M derived: sum of 3 quarters · filed 2022-08-09 | $16.01M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $4.43M 10-Q · filed 2022-05-11 | $7.72M derived: sum of 2 quarters · filed 2022-05-11 | $11.12M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $3.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $6.69M derived: sum of 2 quarters · filed 2022-03-30 | $12.89M 10-K · filed 2022-03-30 | |
| 2020-09-30 | $3.40M 10-Q · filed 2021-11-17 | $9.60M 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |